Accreditation
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Association for Continuing Education designates this educational activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The three stages of this activity are: (A) Pre-assessment Stage, (B) Action Stage, and (C) Post-Assessment Stage. Stages A and C take from 1 to 3 hours each to complete. In stage B you will have the opportunity to implement your personal quality improvement plans over several weeks (minimum 45 days) to improve the care provided to adults with ADHD in your practice. You will receive 5 AMA PRA Category 1 Credits™ for each completed stage and an additional 5 AMA PRA Category 1 Credits ™ for completing all three stages in order, for a maximum of 20 AMA PRA Category 1 Credits™.
Start Date: August 1, 2010
End Date: July 31, 2011
Statement of Need
ADHD in adults is associated with increased health risks and increased healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place issues, increased risks for motor vehicle accidents, greater likelihood of other psychiatric disorders, and higher rates of substance use and abuse. Despite this being a disorder with serious impact on health and overall functioning, the vast majority of adult patients with ADHD remains undiagnosed and, therefore, untreated.1, 2
This activity will enable participants to have a better understanding of the etiology of ADHD, characteristics of ADHD in adults, and appropriate assessment tools to collect meaningful data (interview protocols, rating scales, symptom checklists, etc) for the evaluation of ADHD and co-existing psychiatric conditions. Participants will become more aware of treatment guidelines, safety and efficacy of pharmacologic interventions, and benefits of psychosocial interventions such as cognitive-behavioral therapy, coaching, work/school accommodations, community resources and ADHD education that can help adults with ADHD.
- Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM. (2006). The Prevalence and Correlates of Adult ADHD in the United States: Results from the National Comorbidity Survey Replication. Amer. Jour. of Psychiatry, 163: 724-732.
- Barkley, R.A., Murphy, K.R., & Fischer, M. (2008). ADHD in Adults: What the science says. Guilford Press, New York.
Learning Objectives
After completion of this module, you should be able to:
- Evaluate your current practice behavior and confidence with respect to diagnosing and treating adults with ADHD in your practice
- Describe existing guidelines and best practices in the diagnosis and treatment of ADHD in adults
- Identify evidence-based and consensus-based tools to evaluate symptoms, level of impairment, and relevant history in adult patients suspected of having ADHD
- Identify risks for co-morbidities in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders
- Plan a pharmacologic treatment program for adults diagnosed with simple ADHD and more complex ADHD that is complicated by co-morbidities
- Identify psychosocial treatments for adults diagnosed with ADHD
- Discuss treatment follow-up to optimize success
- Create an action plan that addresses your specific practice behavior that needs improvement with respect to the care of adults with ADHD
^top
Target Audience
Primary care providers including physicians, physician assistants, and nurse practitioners.
Course Directors
Anne Teeter Ellison, Ed.D.
Professor Emeritus
University of Wisconsin
Milwaukee, WI
Gregg Sherman, MD
Family Practice
Margate, Florida
Faculty
Lenard A. Adler, MD
Departments of Psychiatry and Child and Adolescent Psychiatry
New York University School of Medicine
VA Harbor Healthcare System
New York, New York
Russell A. Barkley, Ph.D.
Clinical Professor of Psychiatry
Medical University of South Carolina
Research Professor of Psychiatry at SUNY Upstate Medical School
Syracuse, NY
Kevin Murphy, Ph.D.
The Adult ADHD Clinic of Central Massachusetts
Foxboro, MA
Associate Research Professor at SUNY Upstate Medical Center
Syracuse, NY
J. Russell Ramsay, Ph.D.
Associate Director, ADHD Treatment and Research Program
Assistant Professor of Psychology in Psychiatry Department of Psychiatry
University of Pennsylvania
Philadelphia, PA
Anthony Rostain, M.D., M.A.
Director of Education, Department of Psychiatry
University of Pennsylvania Health System
Philadelphia, PA
Richard L. Rubin, MD
Director, The Vermont Clinical Study Center
Adjunct Associate Professor at Dartmouth Medical College
Hanover, MA
^top
Faculty Disclosure Policy and Disclosures of Course Directores, Faculty and Planners
It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Lenard Adler, MD
Grant/Research Support—Bristol-Myers Squibb, Pfizer, Shire, Eli Lilly, Ortho McNeil/Jannsen/Johnson and Johnson, National Instiitute of Drug Abuse
Advisory Board and Consultant—Eli Lilly, Major League Baseball, Mindsite, Organon, Ortho McNeil/Jannsen/Johnson and Johnson, Shire, i3 Research, Epi-Q, INC
Research—AstraZeneca Pharmaceuticals
Consultant—Otsuka Pharmaceuticals
Russell A. Barkley, Ph.D.
Speaker/Consultant—Eli Lilly, Shire, McNeil, Janssen-Orth, Janssen-Cilag, Novartis
Kevin Murphy, Ph.D.
Speaker’s Bureau—Shire
Russell Ramsay, Ph.D.
Nothing to disclose
Anthony Rostain, MD, MA
Advisory Board—Shire, Ortho-McNeill-Janssen
Richard L. Rubin, MD
Research/Consultant/Speaker’s Bureau—Abbott, Cephalon, Eli Lilly, Johnson & Johnson, Novartis, Shionogi, and Shire
Gregg Sherman, MD
Nothing to disclose
Anne Teeter Ellison, Ed.D.
Nothing to disclose
Other Planning Team Members
Harvey C. Parker, Ph.D., CCMEP
Owner of Specialty Press, Inc. and Health Link Systems, Inc.
Michelle Frisch, MPH, CCMEP
Nothing to disclose
Alan Goodstat, LCSW
Nothing to disclose
Jill Foster, MD, MPH
CE Outcomes, LLC
Nothing to disclose
Nancy Roepke
CE Outcomes, LLC
Nothing to disclose
Stephen Burton
CE Outcomes, LLC
Nothing to disclose
Acknowledgment of Commercial Support
This activity was supported by an educational grant from Lilly USA, LLC . For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Media Used in This Activity
Webcasts, Monographs, Print Material
Hardware/Software Requirements
Web Browser, Adobe Acrobat Reader, Adobe Flash, Mac or PC